168 related articles for article (PubMed ID: 20686235)
1. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of carvedilol in patients with congestive heart failure.
Nikolic VN; Jankovic SM; Velickovic-Radovanović R; Apostolović S; Stanojevic D; Zivanovic S; Stefanovic N; Pesic S; Jevtovic-Stoimenov T; Djuric J; Markovic V; Milovanovic JR
J Pharm Sci; 2013 Aug; 102(8):2851-8. PubMed ID: 23728853
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Graff DW; Williamson KM; Pieper JA; Carson SW; Adams KF; Cascio WE; Patterson JH
J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
Tenero D; Boike S; Boyle D; Ilson B; Fesniak HF; Brozena S; Jorkasky D
J Clin Pharmacol; 2000 Aug; 40(8):844-53. PubMed ID: 10934668
[TBL] [Abstract][Full Text] [Related]
8. Carvedilol: a review of its use in chronic heart failure.
Keating GM; Jarvis B
Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089
[TBL] [Abstract][Full Text] [Related]
9. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
Honda M; Ogura Y; Toyoda W; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
[TBL] [Abstract][Full Text] [Related]
11. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol: a countermeasure to heart failure.
Barkman A; Pooler C
Dimens Crit Care Nurs; 2001; 20(5):11-6. PubMed ID: 22076514
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters.
Läer S; Mir TS; Behn F; Eiselt M; Scholz H; Venzke A; Meibohm B; Weil J
Am Heart J; 2002 May; 143(5):916-22. PubMed ID: 12040358
[TBL] [Abstract][Full Text] [Related]
17. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
18. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Gehr TW; Tenero DM; Boyle DA; Qian Y; Sica DA; Shusterman NH
Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
[TBL] [Abstract][Full Text] [Related]
20. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
